Home / Resource Library / Mosunetuzumab: A bispecific CD20 x CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes

Mosunetuzumab: A bispecific CD20 x CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes

Article provides an overview of mosunetuzumab for treatment of lymphomas.